



George Health



George Health – Governance and Management.
**An Australian Company providing innovative
global treatment solutions for common serious chronic diseases**

Dr Srinivas Akkaraju

Chairman

Srinivas Akkaraju is a former General Partner of Sofinnova Ventures. Prior to Sofinnova, Srinivas was a Managing Director of New Leaf Venture Partners, and prior to that, a Founding Managing Director at Panorama Capital, LLC. Prior to that, Srinivas was a Partner with J.P. Morgan Partners. Srinivas currently serves as a Director of Intercept Pharmaceuticals Inc, Seattle Genetics, Versartis Inc, and aTyr Pharma Inc. Previously, Srinivas served as a Director on the boards of ZS Pharma Inc, Eyetech Pharmaceuticals Inc, Synageva Biopharma Corp, Barrier Therapeutics Inc, and Amarin Corporation plc. Srinivas joined the Board in February 2016.



Yasmin Allen

Director

Yasmin Allen is a Non-Executive Director of Cochlear Limited, Chairman of its Audit Committee and a Member of Cochlear's Technology Committee. She is also a Non-Executive Director of ASX Limited and a Member of the ASX Audit Committee and ASX Clearing and Settlement Board. Yasmin is a Director at Santos Limited and a Member of Santos' Remuneration Committee and Environment, Health and Safety Committee. She is also a Director of the National Portrait Gallery. She is a Fellow of the Australian Institute of Company Directors. Yasmin joined the Board in August 2014.



Professor Stephen MacMahon

Principal Director & founder of TGI

Co-founder of The George Institute for Global Health; Professor of Medicine and James Martin Professorial Fellow, University of Oxford; Professor of Cardiovascular Medicine & Epidemiology, the University of Sydney; Honorary Professor, Peking University Health Science Center; Honorary Consultant, Royal Prince Alfred Hospital (Sydney); Fellow of the Australian Academy of Sciences, the British Academy of Medical Science and the American College of Cardiology and EY Social Entrepreneur of the Year. Stephen was previously Chairman of the Scientific Board of the UK Biobank, Chairman of the World Bank-GIHR Initiative for Cardiovascular Health and Executive Chairman of George Clinical Pty Ltd. Stephen has been a director of the Board since its establishment in 1999.



Scott Featherston

Director

Scott is the Managing Partner at Caerus Capital, a private investment firm that focuses on the health and education sectors in emerging markets. Scott was formerly the Global Health Sector Leader and a Principal Investment Officer for the International Finance Corporation, the private sector arm of the World Bank Group. During his time at IFC (2005-2015), Scott led numerous transactions in the health and education sectors in Africa, MENA, South/East Asia, and Europe and founded the World Bank's Health in Africa initiative. Scott's early career was in engineering and finance. He worked for a global property and project management firm before joining the finance advisory practice of a "Big 4" global consulting firm.



Staph Leavenworth Bakali

President & CEO, Director

Staph has 28 years of considerable senior executive and board level experience in leading large complex and start up organisations in both developed and emerging markets in the global pharmaceutical, biotechnology and not-for profit health arenas. Staph has substantial experience and a proven track record in negotiating and concluding a wide range of public and private sector agreements and partnerships, including cross border mergers and acquisitions. Staph previously was President & Chief Operating Officer of the Clinton Health Access Initiative (CHAI). Prior to CHAI, he held several senior executive and Board positions with leading pharmaceutical and biotechnology companies. Staph holds a Masters in Management from London Business School.



Dr Mohit Kaushal

Director

Dr. Kaushal has had an extensive career within investing, clinical medicine, academia, and public policy. Mohit is a lead investor and board member to numerous transformational companies including Humedica (acquired by Optum Health), Rxante (acquired by Millennium), Change Healthcare (acquired by Emdeon). During his time in the Obama administration, he was a member of the White House Health IT task force; a cross agency team implementing the technology aspects of the ACA and testified to Congress on the application of beneficial technology and payment reform to the Medicare population. He also built and led the first dedicated health care team at the Federal Communications Commission. In addition, his team reformed the Rural Healthcare fund to create the Healthcare Connect Fund, which aligned the funding mechanism with wider health care payment.



Staph Leavenworth Bakali

President & CEO, Director

Staph has 28 years of considerable senior executive and board level experience in leading large complex and start up organisations in both developed and emerging markets in the global pharmaceutical, biotechnology and not-for profit health arenas. Staph has substantial experience and a proven track record in negotiating and concluding a wide range of public and private sector agreements and partnerships, including cross border mergers and acquisitions. Staph previously was President & Chief Operating Officer of the Clinton Health Access Initiative (CHAI). Prior to CHAI, he held several senior executive and Board positions with leading pharmaceutical and biotechnology companies. Staph holds a Masters in Management from London Business School.



Professor Stephen MacMahon

Principal Director & founder of TGI

Co-founder of The George Institute for Global Health; Professor of Medicine and James Martin Professorial Fellow, University of Oxford; Professor of Cardiovascular Medicine & Epidemiology, the University of Sydney; Honorary Professor, Peking University Health Science Center; Honorary Consultant, Royal Prince Alfred Hospital (Sydney); Fellow of the Australian Academy of Sciences, the British Academy of Medical Science and the American College of Cardiology and EY Social Entrepreneur of the Year. Stephen was previously Chairman of the Scientific Board of the UK Biobank, Chairman of the World Bank-GIHR Initiative for Cardiovascular Health and Executive Chairman of George Clinical Pty Ltd. Stephen has been a director of the Board since its establishment in 1999.



Dr Eliot Charles

CEO George Medicines

Dr Charles has previously been a Venture Partner at New Leaf Venture Partners, and a Partner at Apax Partners, Inc., a global private equity firm. Previous positions in the biopharmaceutical industry include COO at Principia Biopharma, Head, External R&D Affairs at Amgen, and Director, Business Development at Genentech, Inc. He holds a Ph.D. in Neuroscience from the Massachusetts Institute of Technology and an M.B.A. from the University of Chicago.



Glenn Kerkhof

Executive Chairman George Clinical

Glenn is Executive Chairman of George of Clinical. Glenn has over 22 years' experience in the contract research or drug development industry and joined George Clinical from Chiltern where he was Chief Executive Officer. Prior to Chiltern, Glenn served as Vice President, Clinical Services for Charles River Laboratories and as Vice President, Clinical Europe for Inveresk Research. In addition, he is also non-executive director of Cell Care Australia Pty. Ltd. and Immunoglobul Pty. Ltd. He holds a Bachelor of Commerce from Deakin University (Australia) and a Masters of Business Administration from the University of Edinburgh (UK).



Professor Anushka Patel

CEO George Care

Anushka is a Professor of Medicine at The University of Sydney and a cardiologist at Royal Prince Alfred Hospital in Sydney, Australia. She undertook her medical training at the University of Queensland, with subsequent postgraduate research degrees from Harvard University and the University of Sydney. As the Chief Scientist of the George Institute for Global Health, she has a key role in developing and supporting global strategic initiatives across the organisation, especially with international collaborators. Her personal research interests focus on developing innovative solutions for delivering affordable and effective chronic disease care in the community and in acute care hospital settings. Anushka currently leads research projects relating to these interests in Australia, Europe, China and India.



Tim Regan

Chief Operating Officer

Chief Financial Officer

Director and former President of the Financial Executives Institute in Australia; former Director of Thomas & Coffey; Bachelor of Economics, the University of Sydney; Fellow of the Australian Institute of Company Directors, Institute of Chartered Accountants and Australian Property Institute. Prior experience includes former COO of Mirvac Group; CEO of TJS Services; Commercial Manager for Sydney Organising Committee for the Olympic Games; and Senior Manager at PricewaterhouseCoopers.



Michael Hawker AM

Chairman

Michael Hawker is a Non-Executive Director of Aviva Plc Group (UK), the Macquarie Group Limited, Macquarie Bank Limited and Washington H. Soul Pattinson. Michael is Chair of the Australian Business and Community Network Foundation, and a Non-Executive Director of the Rugby World Cup Limited. His former Executive roles include Chair of the Australian Rugby Union, Non-Executive Director of SANZAR Pty Limited, Member of the Executive Committee, World Rugby Council, CEO and Managing Director of Insurance Australia Group, Group Executive of Business and Consumer Banking at Westpac, Executive Director of Citibank International in Europe, and a Deputy Managing Director of Citibank in Australia. He is a Senior Fellow of the Financial Services Institute of Australia and a Fellow of the Australian Institute of Company Directors. Michael joined the Board in February 2011.



Russell Aboud

Russell Aboud has worked in the global investment industry both domestically and internationally for over 29 years, the majority of time as a Managing Director in Sydney and London for UBS. Currently, Russell is the Executive Chairman and a Founding Partner of Manikay Partners, a New York based multi-strategy global investment firm. Former appointments include Non-Executive Director of the Australian Securities Exchange, Chairman of Ord Minnett and Senior Advisor to J.P. Morgan Australia. Russell joined the Board in August 2013.



Dr Srinivas Akkaraju

Srinivas Akkaraju is a former General Partner of Sofinnova Ventures. Prior to Sofinnova, Srinivas was a Managing Director of New Leaf Venture Partners, and prior to that, a Founding Managing Director at Panorama Capital, LLC. Prior to that, Srinivas was a Partner with J.P. Morgan Partners. Srinivas currently serves as a Director of Intercept Pharmaceuticals Inc, Seattle Genetics, Versartis Inc, and aTyr Pharma Inc. Previously, Srinivas served as a Director on the boards of ZS Pharma Inc, Eyetech Pharmaceuticals Inc, Synageva Biopharma Corp, Barrier Therapeutics Inc, and Amarin Corporation plc. Srinivas joined the Board in February 2016.



Yasmin Allen

Yasmin Allen is a Non-Executive Director of Cochlear Limited, Chairman of its Audit Committee and a Member of Cochlear's Technology Committee. She is also a Non-Executive Director of ASX Limited and a Member of the ASX Audit Committee and ASX Clearing and Settlement Board. Yasmin is a Director at Santos Limited and a Member of Santos' Remuneration Committee and Environment, Health and Safety Committee. She is also a Director of the National Portrait Gallery. She is a Fellow of the Australian Institute of Company Directors. Yasmin joined the Board in August 2014.



Gina Anderson

Gina Anderson is an experienced Company Director. She is currently a Non-Executive Director of GDI Property Group and GDI Funds Management; Advisory Board Member of the Australian Charities and Not-for-profits Commission (ACNC); Co-Founder and Chair of Women's Community Shelters; Advisory Board Member, Initiative on Corporate Philanthropy, The Conference Board, USA; and Philanthropy Fellow, Centre for Social Impact, University of NSW. Gina was Executive Director and CEO of Philanthropy Australia from 2005 to 2010. She has held corporate affairs, human resources and general management roles, including seven years in senior management roles at Westpac. Gina joined the Board in February 2012, and is Chair of its Development Committee.



David Armstrong

David Armstrong is a Non-Executive Director of the National Australia Bank (since August 2014), Chair of the Risk Committee and a Member of its Audit Committee and Information Technology Committee. David is also a Director of the Opera Australia Capital Fund Limited (since May 2013), and a Trustee of the Australian Museum (since January 2014) and Lizard Island Reef Research Foundation (since April 2014). David has more than 30 years' experience in professional services. David is a Fellow of the Institute of Chartered Accountants in Australia and a Member of the Australian Institute of Company Directors. David joined the Board in October 2014, and is Chair of its Finance, Risk and Audit Committee.



David Baffsky AO

David Baffsky has had an extensive legal career specialising in commercial and fiscal law. David is Honorary Chairman (formerly Executive Chairman between 1993 and 2008) of Accor Asia Pacific. He is Chairman of the ASX listed Ariadne Australia Ltd, Chairman of Investa Property Group, and Board Member of Sydney Olympic Park Authority, Destination NSW and the Australian Brandenburg Orchestra. David joined the Board in August 2016.



Melinda Conrad

Melinda Conrad is currently a Non-Executive Director of OzForex Limited, Chair of its Remuneration Committee and Member of its Audit and Risk Committee. She is a Non-Executive Director of The Reject Shop Limited, Chair of its Remuneration Committee and Member of its Audit and Risk Committee. Melinda is also a Director of the Centre for Independent Studies, Member of the Minter Ellison Advisory Board and Member of the Australian Institute of Company Directors Corporate Governance Committee. Melinda is a Fellow of the Australian Institute of Company Directors. Melinda joined the Board in November 2015.




Catherine Livingstone AO

Catherine Livingstone spent 20 years working in the field of implantable medical devices, including six years as CEO and Managing Director of Cochlear Limited. Catherine is Chairman of the Commonwealth Bank Australia Limited and a Non-Executive Director of Worley Parsons Limited and Saluda Medical Pty Ltd. She is President of the Business Council of Australia, and a Member of the Commonwealth Science Council, the Growth Centres Advisory Committee, and is President of the Australian Museum. Catherine's former roles include Chairman of Telstra Corporation Limited, Chair of the Commonwealth Scientific and Industrial Research Organisation (CSIRO), President of Chief Executive Women, Chair of The Australian Business Foundation, Non-Executive Director of the Macquarie Group, and a Member of the New South Wales Innovation and Productivity Council. Catherine joined the Board in August 2012.



Paul McClintock AO

Paul McClintock is Chairman of Myer Holdings Limited, NSW Ports, I-MED Network, Sydney Health Partners, Committee for Economic Development of Australia, and a Director of St Vincent's Health Australia Limited. Paul has served as the Secretary to Cabinet and Head of the Cabinet Policy Unit reporting directly to the Prime Minister as Chairman of Cabinet, supervising Cabinet processes and acting as the Prime Minister's most senior personal policy adviser. Paul graduated in Arts and Law from the University of Sydney and is an Honorary Fellow of the Faculty of Medicine. Paul joined the Board in October 2013.



Professor Robyn Norton

Principal Director & founder

Co-founder of The George Institute for Global Health; Professor of Global Health and James Martin Professorial Fellow, University of Oxford; Professor of Public Health, the University of Sydney; Honorary Professor, Peking University Health Science Center; Honorary Consultant Epidemiologist, Royal Prince Alfred Hospital (Sydney); Member, Health Care Committee, NHMRC; Chair Emeritus, Road Traffic Injuries Research Network. Robyn has been a director of the Board since its establishment in 1999.



Professor Stephen MacMahon

Principal Director & founder

Co-founder of The George Institute for Global Health; Professor of Medicine and James Martin Professorial Fellow, University of Oxford; Professor of Cardiovascular Medicine & Epidemiology, the University of Sydney; Honorary Professor, Peking University Health Science Center; Honorary Consultant, Royal Prince Alfred Hospital (Sydney); Fellow of the Australian Academy of Sciences, the British Academy of Medical Science and the American College of Cardiology and EY Social Entrepreneur of the Year. Stephen was previously Chairman of the Scientific Board of the UK Biobank, Chairman of the World Bank-GIHR Initiative for Cardiovascular Health and Executive Chairman of George Clinical Pty Ltd. Stephen has been a director of the Board since its establishment in 1999.

